CDER Succession: Woodcock's Responsibilities Mount With No Clear #2 In Sight
If FDA decides to replace Richard Moscicki, that individual will almost automatically be seen as Janet Woodcock’s heir-apparent at CDER, should she choose to retire.
You may also be interested in...
Patrizia Cavazzoni, Janet Woodcock's new #2, has a background similar to Richard Moscicki, CDER's previous deputy director for operations.
In memo to then-Commissioner Califf during review of Sarepta's Exondys 51, Jenkins wrote that he was concerned about leaving OND in hands of CDER director upon his retirement.
Peter Stein, a leader in diabetes drug development programs, joins FDA as a new administration is about to come in; he fills one of 676 CDER vacancies.